Navigation Links
Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
Date:10/29/2007

FAJARDO, Puerto Rico and CORONA, Calif., Oct. 29 /PRNewswire-FirstCall/ -- Warner Chilcott Company, Inc. and Watson Pharmaceuticals, Inc. announced today that under a supply agreement between Warner Chilcott and Watson Pharma, Inc., Watson has launched Tilia(TM) Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), the generic version of Warner Chilcott's oral contraceptive Estrostep(R) Fe.

Under the terms of the agreement, Warner Chilcott will supply Tilia(TM) to Watson Pharma, which will market, sell and distribute the generic product in the United States. Warner Chilcott will receive a share of the profits from Watson's sales of the generic product in the U.S. market. Further details on the agreement have not been disclosed.

Warner Chilcott Company Inc. is a subsidiary of Warner Chilcott Limited (Nasdaq: WCRX) WCRX-G.

Watson Pharma, Inc. is a subsidiary of Watson Pharmaceuticals, Inc. (NYSE: WPI).

About Warner Chilcott

Warner Chilcott is a specialty pharmaceutical company focused on developing, manufacturing, marketing and selling branded prescription pharmaceutical products in women's healthcare and dermatology in the U.S.

Read more on http://www.warnerchilcott.com.

Warner Chilcott's Forward Looking Statements:

This press release contains forward-looking statements, including statements concerning our product development efforts. Th
'/>"/>

SOURCE Warner Chilcott Company, Inc.; Watson Pharmaceuticals,Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Charter and Time Warner to partner on fiber optics
2. Deltanoid Pharmaceuticals begins phase II osteoporosis study
3. The Coming of Biotech Generic Pharmaceuticals
4. Speaker announces business members of IT Task Force
5. Doyle announces technology tax credits for Berbee
6. Doyle announces new energy, global warming policies
7. Doyle, WARF announce partnership to lure stem cell companies
8. Doyle announces $80M renewable energy strategy
9. GE announces first installation of Discovery VCT
10. UWM announces winners of RGI awards
11. Third Wave announces two senior management appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... July 30, 2014 With the ... of personal health expenditure as well as the ... system, China diagnostic reagent industry has been developing ... 90%. In 2013, Chinese in vitro diagnostics market ... came from in vitro diagnostic reagents. , ...
(Date:7/30/2014)...  Orexigen Therapeutics, Inc. (Nasdaq: OREX ) ... of Outstanding Issues (LOI) from the European Medicines Agency,s ... the NB32 Marketing Authorization Application (MAA). NB32 (naltrexone sustained ... candidate being evaluated for weight loss. The ... were adequately addressed by the Company based in part ...
(Date:7/30/2014)... , July 30, 2014  RXi Pharmaceuticals ... biotechnology company focused on discovering, developing and ... needs using RNA-targeted technologies, today announced that ... RXI-109, for the reduction of recurrence of ... has been initiated. Logo - ...
(Date:7/30/2014)... Immunology Summit-2014 will ... Investigators, scientists in the field, which includes prominent ... Case Western Reserve University School of Medicine, USA, ... “The effects of recombinant human IL-6 and ... Arya Biragyn, a Senior investigator at National Institute ...
Breaking Biology Technology:China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 2China Diagnostic Reagent Industry Report, 2013-2016 | Researchmoz 3Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5Unveiling Breakthroughs in Clinical & Cellular Immunology 2Unveiling Breakthroughs in Clinical & Cellular Immunology 3
... Wis . - Gov. Jim Doyle has announced ... expand on the Fitchburg Technology Campus, will receive $250,000 in ... plans to invest in a new 43,250-square-foot office building and ... is part of the Fitchburg Technology Campus. , ,The ...
... TomoTherapy has raised $223 million, the amount it had ... completed earlier today. , ,TomoTherapy, a portfolio company of ... per share, and expects to receive $185 million in net ... 10.7 million shares, and the per-share price closed at $22.67. ...
... pace of healthcare information technology adoption doesn't pick up ... regarding healthcare costs, according to John Wade, who delivered ... 2007 . , ,Within healthcare IT, a subject that ... than the possibilities, there is a growing fear that ...
Cached Biology Technology:TomoTherapy raises $223 million in IPO 2DHC 2007: Without fuller IT adoption, health costs might drain America's wealth 2DHC 2007: Without fuller IT adoption, health costs might drain America's wealth 3
(Date:7/30/2014)... , July 30, 2014 NexID ... and liveness detection solutions for the biometric authentication ... industry consortium revolutionizing online authentication with standards for ... Cornett , "The decision to join FIDO Alliance ... authentication pervasive in use. We believe the FIDO ...
(Date:7/30/2014)... To help Americans make better decisions about what they ... year proposed significant changes to the Nutrition Facts label ... An article in Chemical & Engineering News ... Society, explains the suggested updates and the fight ... at C&EN, points out that while the Nutrition Facts ...
(Date:7/30/2014)... Chown has been awarded the Scientific Committee on ... Antarctic Research. , SCAR, an inter-disciplinary international science ... scientific research in the Antarctic region, and on ... Earth system. The organisation also provides scientific advice ... for governing the region. , The medal is ...
Breaking Biology News(10 mins):NexID Biometrics Joins the FIDO Alliance 2
... COLLEGE STATION This time of year, the word "virus" ... everyone goes to great lengths to avoid. But scientists for ... least some viruses can be put to work to help us. ... Dr. Herman Scholthof, to be published in the January issue of ...
... BEER-SHEVA, ISRAEL January 4, 2010 - A researcher from ... integrated interpretation of Autism Spectrum Disorders (ASD), which makes ... between ASD and other conditions. In an ... The Neuroscientist titled: "The Medial Prefrontal Cortex and ...
... As it turns out, children were not the only ones ... this past holiday season. In a new research report published ... Leukocyte Biology ( http://www.jleukbio.org ), a team of scientists ... for Children show how a compound from licorice root (glycyrrhizin ...
Cached Biology News:Virus may chauffeur useful 'packages' into plants 2A trip to the candy store might help ward off rare, but deadly infections 2
... Preparation contains a unique β-agarose digesting enzyme ... of intact DNA and RNA from low ... in TAE, TBE, MOPS, or phosphate buffers. ... the TAE, TBE, MOPS, and phosphate electrophoresis ...
... demand is causing shortages in your laboratory or ... cause unwanted distractions, problems and delays. ... work and endeavour! Bring us your idea and ... internationally. We work under ISO 9001 quality assurance ...
... demand is causing shortages in your laboratory or ... cause unwanted distractions, problems and delays. ... work and endeavour! Bring us your idea and ... internationally. We work under ISO 9001 quality assurance ...
Topoisomerase I...
Biology Products: